ACCELERATE Data Transparency Initiative
Eli Lilly, in collaboration with the Cleveland Clinic Coordinating Center for Clinical Research (C5Research), will provide access to the individual patient data from the ACCELERATE trial to enable the advancement of cardiovascular research. Proposals will be accepted beginning May 2018. This access is provided in a timely fashion after the primary publication. Researchers need to have an approved research proposal submitted through https://redcap.ccf.org/redcap/surveys/?s=L4FHCDJW8N

 

Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.



Most Recent Publication:

ADCY9 Genetic Variants and Cardiovascular Outcomes with Evacetrapib in Patients with High Risk
Vascular Disease A Nested Case-Control Study

JAMA Cardiology, published online March 11, 2018


Primary Publication:

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
N Engl J Med 2017;376:1933-42